Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Endocrinology & Hormones >  GPR agonists >  GSK1292263

GSK1292263

Basic information Safety Supplier Related

GSK1292263 Basic information

Product Name:
GSK1292263
Synonyms:
  • CS-417
  • GPR119 receptor agonist GS1292263
  • 3-Isopropyl-5-(4-(((6-(4-(methylsulfonyl)phenyl)pyridin-3-yl)oxy)methyl)piperidin-1-yl)-1,2,4-
  • 5-[[[1-[3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]methyl]oxy]-2-[4-(methylsulfonyl)phenyl]pyridine
  • 3-isopropyl-5-(4-(((6-(4-(Methylsulfonyl)phenyl)pyridin-3-yl)oxy)Methyl)piperidin-1-yl)-1,2,4-oxadiazole
  • 3-Isopropyl-5-(4-(((6-(4-(methylsulfonyl)phenyl)pyridin-3-yl)oxy)methyl)piperidin-1-yl)-1,2,4-oxa
  • GSK1292263
  • 5-((1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methoxy)-2-(4-(methylsulfonyl)phenyl)pyridine
CAS:
1032823-75-8
MF:
C23H28N4O4S
MW:
456.56
Product Categories:
  • Inhibitors
Mol File:
1032823-75-8.mol
More
Less

GSK1292263 Chemical Properties

Boiling point:
655.1±65.0 °C(Predicted)
Density 
1.23
storage temp. 
Store at -20°C
solubility 
≥21.1 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form 
solid
pka
4.75±0.32(Predicted)
color 
White to off-white
More
Less

GSK1292263 Usage And Synthesis

Biological Activity

gsk1292263 is a novel agonist of gpr119 receptor agonist and is used for the treatment of type 2 diabetes.gpr119 is described as a class a (rhodopsin-type) orphan gpcr with no close primary sequence relative in the human genome. the activation of gpr119 increases the intracellular accumulation of camp, resulting in enhanced insulin secretion from pancreatic β-cells and increased release of the gut peptides glp-1 (glucagon-like peptide 1), gip (glucose-dependent insulinotropic peptide) and pyy (polypeptide yy).in vitro, gsk1292263 treatment displayed little inhibition towards cyps (cyp1a2, 2c9, 2c19, 2d6, 3a4), p-gp, oatp1b3, or oct2. however, gsk1292263 inhibited bcrp and oatp1b1, which are transporters involved in statin disposition 1.in the glucose tolerance test in rats, administration of gsk-1292263 significantly increases the peak insulin response and insulin auc (0-15 min) as compared with the values in the vehicle control. the upregulation of insulin was found to correlate with an increase in the glucose disposal rate. in hyperinsulinemic-euglycemic clamps, gsk-1292263 administration on sprague-dawley rats at dose of 10 or 30 mg/kg 2 hours prior to insulin infusion can promote glucagon secretion with no increase of blood glucose levels 2.

target

GPR119

References

1. polli jw, hussey e, bush m, et al. evaluation of drug interactions of gsk1292263 (a gpr119 agonist) with statins: from in vitro data to clinical study design. xenobiotica; the fate of foreign compounds in biological systems. 2013;43(6):498-508.2. zhu x, huang d, lan x, et al. the first pharmacophore model for potent g protein-coupled receptor 119 agonist. european journal of medicinal chemistry. 2011;46(7):2901-2907.

GSK1292263Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Email
sales@jingyan-chemical.com
China DongFan Chemical Co.,LTD
Tel
86-0571-85151182
ChemCell Biomedicine Co.,Ltd.
Tel
020-13556033878 2965585218 13556033878
Email
chemcell@hotmail.com